Business Update France: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Business Update France.

Press releases published on March 24, 2026

Mar. 24, 2026

Aveta Biomics Announces Podium Presentation of Registrational Phase 3 Head and Neck Cancer Trial at AHNS 2026 Conference

Indeterminate EIN Presswire

Mar. 24, 2026

Fort du succès du Guide anti-OTA, Doyield décrypte sur BFM Business le nouvel équilibre du Revenue Management hôtelier

Indeterminate EIN Presswire

Mar. 24, 2026

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Indeterminate GlobeNewswire

Mar. 24, 2026

DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris

Indeterminate GlobeNewswire

Mar. 24, 2026

Armenian Personal Development Programs Launch in LA and Yerevan

Indeterminate EIN Presswire

Mar. 24, 2026

[Press Release] Ipsos - Appointment of Alexandre Boissy as Deputy Chief Executive Officer

Indeterminate GlobeNewswire

Mar. 24, 2026

[Communiqué de presse] Ipsos - Nomination d’Alexandre Boissy en tant que Directeur général adjoint

Indeterminate GlobeNewswire

Mar. 24, 2026

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

Indeterminate GlobeNewswire

Mar. 24, 2026

Transgene poursuit ses avancées pour transformer l’avenir du traitement des cancers au stade précoce avec des vaccins thérapeutiques individualisés reposant sur des néoantigènes (VTIN), [...]

Indeterminate GlobeNewswire

Mar. 24, 2026

Press release: Availability of the Q1 2026 aide-mémoire

Indeterminate GlobeNewswire

Mar. 24, 2026

Technip Energies convenes its 2026 Annual General Meeting

Indeterminate GlobeNewswire

Mar. 24, 2026

Technip Energies convoque son assemblée générale annuelle 2026

Indeterminate GlobeNewswire

Mar. 24, 2026

Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »

Indeterminate GlobeNewswire

Mar. 24, 2026

ABC arbitrage : Résultats annuels 2025

Indeterminate GlobeNewswire

Mar. 24, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Indeterminate GlobeNewswire

Mar. 24, 2026

ABC arbitrage: 2025 Results

Indeterminate GlobeNewswire

Mar. 24, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse  

Indeterminate GlobeNewswire

Mar. 24, 2026

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Indeterminate GlobeNewswire